hengrui glp-1 Kailera, to advance oral obesity drug into 2 new trials Hengrui and Kailera report positive

Adam Gilden, MD, MSCE Medical Reviewer Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Me

doi: 10.1042/bj3480607

MAGA math again

This hormone signals your brain to stop eating, slows down how fast food leaves your stomach, and improves how your body handles insulin

How to Evaluate GLP-1 Sources: A Clinical and Safety Framework When selecting where to obtain GLP-1, prioritize: (1) licensed pharmacy oversight (503A compounding or traditional retail), (2) qualified prescribing provider with weight management or metabolic experience, (3) transparent pricing and no hidden fees, (4) baseline health screening (kidney function, thyroid status, cardiovascular history), and (5) ongoing clinical monitoring with dose adjustments based on response and tolerability

This multi-receptor mechanism distinguishes retatrutide from earlier generations of incretin-based research compounds including GLP-1 mono-agonists such as semaglutide, and dual GIP/GLP-1 agonists such as tirzepatide by introducing glucagon receptor activation as an additional metabolic axis